Dnyanamay

Open Access Open Access  Restricted Access Subscription Access

Treatment of Diabetic Foot Ulcers with Autologous Bone Marrow Cells, Platelets, Fibrin Glue and Collagen Matrix


Affiliations
1 Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India
2 Resident JR 3, Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India
 

Objectives: To study the role of autologous bone marrow in healing chronic diabetic wound And to evaluate the cost effectiveness

Methods: Autologous Bone Marrow aspirated under spinal anaesthesia and Bone Marrow-total nucleated cells were separated and concentrated. 100 mL peripheral blood were taken and platelets and fibrin glue were prepared according to standard procedures. Then it was locally applied and regular dressing done. Pt was followed for six weeks, with assessing the wound every week.

Results: 35 patients were studied and 3 patients had complete closure of the wound. One patient did not show significant improvement. Rest all the patients had significant reduction of wound size after 6 weeks.

Conclusion: Patients treated with autologus bone marrow cells, platelets, fibrin glue and collegan matrix did show significant reduction in the wound size. Use of these components was safe and effective and this treatment had been cost effective.


Keywords

Bone Marrow, Platelets, Fibrin Glue, Collegan Matrix.
User
Notifications
Font Size

  • Kleopatra Alexiadou and John Doupis Management of Diabetic Foot Ulcers PMCID: PMC3508111

  • Abbott CA, Carrington AL, Ashe H, North-West Diabetes Foot Care Study et al. The North-West Diabetes FootCare Study: incidence of, and risk factors for, new diabetic foot ulceration in a communitybased patient cohort. Diabet Med. 2002;19:377–384. doi: 10.1046/j.1464-5491.2002.00698.x. [PubMed] [Cross Ref]

  • Centers for Disease Control and Prevention Lower extremity disease among persons aged ≥40 years with and without diabetes—United States, 1999–2002. MMWR Morb Mortal Wkly Rep. 2005;54:1158–1160. [PubMed]

  • Lauterbach S, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care. 2010;19:333–337. [PubMed]

  • Viswanathan V. The diabetic foot: perspectives from Chennai, South India. Int J Low Extrem Wounds. 2007 Mar; 6(1):34-6.

  • Fard AS, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract. 2007;61:1931 – 8.

  • Brod M. Quality of life issues in patients with diabetes and lower extremity ulcers: patients and care givers. Qual Life Res. 1998;7:365 – 72.

  • Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcer in patients with diabetes. JAMA. 2005;293:217 – 28.

  • Center for Disease Control and Prevention. National Diabetes Fact Sheet. National Estimates on Diabetes, 2000 – 2001. Center for Disease Control and Prevention,Atlanta, GA. http://www.cdc.gov/diabetes/pubs/estimates.htm. Accessed 18 November 2003.

  • Mendez MV, Stanley A, Phillips T, Murphy M, Menzoian JO, Park HY. Fibroblasts cultured from distal lower extremities in patients with venous refl ux display cellular characteristics of senescence. J Vasc Surg. 1998;28:1040 – 50.

  • Raffetto JD, Mendez MV, Phillips TJ, Park HY, Menzoian JO. The effect of passage number on fi broblast cellular senescence in patients with chronic venous insuffi ciency with and without ulcer. Am J Surg. 1999;178:107 – 12.

  • Vande Berg JS, Rudolf R, Holland C, Haywood-Reid PL. Fibroblast senescence in pressure ulcers. Wound Repair Regen. 1998;6:38 – 49.

  • Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999;7:442 – 52.

  • Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. Br Med J. 2002;324:160 – 3.

  • Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201 – 7.

  • Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol. 2003;139:510 – 16.

  • Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classifi cation and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204:322 – 30.

  • Laurens N, Koolwijk P, de Maat MPM. Fibrin structure and wound healing. J Thromb Haemost. 2006;4:932 – 9.

  • Ichioka S, Kouraba S, Sekiya N, Ohura N, Nakatsuka T. Bone marrow-impregnated collagen matrix for wound healing: experimental evaluation in a microcirculatory model of angiogenesis, and clinical experience. Br J Plast Surg. 2005;58: 1124 – 30.

  • Rogers LC, Bevilacqua NJ, Armstrong DG. The use of marrowderived stem cells to accelerate healing in chronic wounds. Int Wound J. 2008;5:20 – 5.

  • Humpert PM, Bartsch U, Konrade I, Hammes HP, Morcos M, Kasper M, et al. Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient. Exp Clin Endocrinol Diabetes. 2005; 113:538 – 40.

  • Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. Br Med J. 2002;324:160 – 3.

  • Koliakos G, Alamdari DH, Tsagias N, Kouzi-Koliakos K, Michaloudi E, Karagiannis V. A novel high-yield volumereduction method for the cryopreservation of UC blood units. Cytotherapy. 2007;9:654 – 9

  • Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105: 369 – 77.

  • Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143 – 7.

  • Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 200;366:1736 – 43.

  • Lorenz HP, Longaker MT. Wounds: Biology, Pathology, and Management. Stanford: Stanford University Medical Center; 2003. p. 77 – 88.


Abstract Views: 131

PDF Views: 80




  • Treatment of Diabetic Foot Ulcers with Autologous Bone Marrow Cells, Platelets, Fibrin Glue and Collagen Matrix

Abstract Views: 131  |  PDF Views: 80

Authors

Gajanan Ekbote
Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India
Sarfraj Pathan
Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India
Arvind Giram
Resident JR 3, Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India
Ahsan Zuberi
Resident JR 3, Dept. of Surgery, B.J. Govt. Medical College, and Sasson General Hospital, Pune (M.S), India

Abstract


Objectives: To study the role of autologous bone marrow in healing chronic diabetic wound And to evaluate the cost effectiveness

Methods: Autologous Bone Marrow aspirated under spinal anaesthesia and Bone Marrow-total nucleated cells were separated and concentrated. 100 mL peripheral blood were taken and platelets and fibrin glue were prepared according to standard procedures. Then it was locally applied and regular dressing done. Pt was followed for six weeks, with assessing the wound every week.

Results: 35 patients were studied and 3 patients had complete closure of the wound. One patient did not show significant improvement. Rest all the patients had significant reduction of wound size after 6 weeks.

Conclusion: Patients treated with autologus bone marrow cells, platelets, fibrin glue and collegan matrix did show significant reduction in the wound size. Use of these components was safe and effective and this treatment had been cost effective.


Keywords


Bone Marrow, Platelets, Fibrin Glue, Collegan Matrix.

References